News - Page 2 of 5 - Immusoft

Investors & Media

Publications & Presentations

Engineering B Cells With Immusoft’s Sean Ainsworth

December 9, 2025

Business of Biotech
Press Releases

Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I

October 21, 2025

PR Newswire
Press Releases

In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I

October 7, 2025

Immusoft
Publications & Presentations

Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells

May 16, 2025

Beyond Biotech
Press Releases

Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial

May 13, 2025

PR Newswire
Articles

Immusoft Goes For Cell Therapy Plan ‘B’

February 26, 2025

Citeline
Publications & Presentations

Safety and Initial Activity of Autologous Human B Cells Genetically Engineered to Express Human Iduronidase Using the Sleeping Beauty Transposon System: Results from a First-in-Human Clinical Trial in Subjects with MPS I

February 7, 2025

WORLDSymposium
Press Releases

Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium™ 2025

January 27, 2025

PR Newswire
Publications & Presentations

RARECast: Engineering B cells to Produce Therapeutic Proteins

December 19, 2024

Global Genes
Publications & Presentations

MPS I Clinical Update and Outreach Webinar: Highlights

December 17, 2024

Immusoft